Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RBOT
RBOT logo

RBOT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
40.98M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
251.10K
EV/OCF(TTM)
--
P/S(TTM)
--
Vicarious Surgical Inc. is a robotics company, developing technology to improve surgical procedures. The Company is combining advanced miniaturized robotics, computer science, sensing and three-dimensional (3D) visualization to build a single-port surgical robot, called the Vicarious Surgical System, that helps surgeons to perform minimally invasive surgery. The Vicarious Surgical System is capable of incision sizes of approximately 1.8 centimeters. The Vicarious Surgical System consists of a camera and instrument arms, surgeon console and patient cart. The Vicarious Surgical System has a high-performance stereoscopic camera that, when combined with robotic motion, provides full 360-degree viewing capability and is being developed to continuously map the depth of the abdominal cavity. The Vicarious Surgical System surgeon console is designed to provide all the systems necessary for the surgeon in visualizing the surgical field and controlling all the motions of the robot.
Show More

Events Timeline

(ET)
2026-03-16
09:30:00
Vicarious Surgical Expects 2026 Cash Burn to Drop to $19 Million
select
2026-03-04 (ET)
2026-03-04
07:20:00
Vicarious Surgical Receives NYSE Delisting Notice
select
2026-03-03 (ET)
2026-03-03
16:10:00
NYSE Initiates Delisting Procedures Against Vicarious Surgical
select
2025-12-29 (ET)
2025-12-29
16:20:00
Vicarious Surgical Enters Strategic Partnership with Global Digital Engineering Firm
select
2025-12-12 (ET)
2025-12-12
16:40:00
Vicarious Surgical Files $100M Mixed Securities Shelf
select
2025-12-03 (ET)
2025-12-03
07:10:00
Vicarious Surgical Raises 2025 Cash Burn Guidance to $45M
select
2025-11-12 (ET)
2025-11-12
16:26:15
Vicarious Surgical announces Q3 adjusted EPS of $1.91, falling short of consensus estimate of $2.33
select
2025-09-25 (ET)
2025-09-25
16:15:54
Joseph Doherty Appointed Chairman of the Board at Vicarious Surgical
select
2025-07-31 (ET)
2025-07-31
16:38:37
Vicarious Surgical names Stephen From CEO
select

News

Newsfilter
8.5
03-30Newsfilter
PinnedVicarious Surgical Completes Surgical Instrument Testing
  • Successful Testing: Vicarious Surgical has completed initial integrated benchtop testing of its full suite of surgical instruments, marking a significant step toward clinical readiness for ventral hernia repair, which is expected to advance design validation and clinical preparation.
  • System Performance Evaluation: The testing included the company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, with successful system-level performance evaluations providing critical support for de-risking the path to first-in-human use, enhancing the company's competitiveness in minimally invasive surgery.
  • Electrical Performance Validation: The monopolar scissors demonstrated strong motion and cutting capabilities after standard automated calibration, confirming stability under clinically relevant operating conditions and further validating the system's reliability following successful performance in prior porcine lab studies.
  • Future Development Plans: Following the successful completion of benchtop testing, the company will advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, continuing preparations for the first clinical use and ensuring the achievement of the design freeze milestone as scheduled.
Newsfilter
8.5
03-25Newsfilter
Vicarious Surgical Receives Approval for OTCQB Listing
  • Market Transparency Boost: Vicarious Surgical's Class A common stock began trading on the OTCQB on March 24, 2026, aimed at enhancing market visibility and facilitating market maker participation, thereby increasing liquidity to support the company's strategic goal of a Nasdaq listing.
  • Capital Markets Strategy Progress: CEO Stephen From stated that the OTCQB listing represents a significant step in their capital markets strategy, expected to provide better liquidity for shareholders and pave the way for a future Nasdaq listing.
  • Technological Innovation Background: Founded in 2014, Vicarious Surgical focuses on developing human-like surgical robots to enhance the efficiency of minimally invasive surgeries and improve patient outcomes, backed by notable investors including Bill Gates, highlighting its technological potential and market appeal.
  • Future Development Outlook: The company aims to achieve design freeze by the end of 2026, and with the OTCQB trading, Vicarious Surgical hopes to re-engage a broader investor base through ongoing operational progress, further driving business growth.
seekingalpha
9.5
03-09seekingalpha
Vicarious Surgical Reports Q4 Loss, Updates Cash Burn Guidance
  • Earnings Miss: Vicarious Surgical reported a Q4 non-GAAP EPS of -$1.65, missing expectations by $0.28, indicating challenges in profitability that could impact investor confidence.
  • Cash Position: As of December 31, 2025, the company had $9.8 million in cash and investments, which, while relatively low, supports short-term operations and reflects urgency in financial management.
  • Cash Burn Rate: The cash burn rate for 2025 was $45.1 million, below the initial guidance of $50 million, indicating some progress in cost control that may lay the groundwork for future financial stability.
  • Future Guidance: Vicarious Surgical updated its cash burn guidance for 2026 to approximately $19 million, demonstrating optimism regarding operational efficiency improvements and future financial health.
Newsfilter
3.5
01-12Newsfilter
Vicarious Surgical Completes In-Vivo Lab in December 2025, Advancing Robotic Surgery System Development
  • Successful Lab Testing: Vicarious Surgical completed an in-vivo lab with porcine models in December 2025, marking a significant advancement in the development of its robotic surgery system, which is expected to facilitate a design freeze by the end of 2026.
  • Key Procedure Evaluation: During the lab, surgeons independently performed critical elements of a ventral hernia repair, validating the feasibility of the pre-DV system and providing essential data for future design decisions.
  • System Performance Assessment: The lab included three independent development protocols that evaluated core system capabilities such as instrument articulation, visualization, and system integration in a realistic surgical environment, ensuring minimized technical risks.
  • Data-Driven Optimization: The data generated and surgeon feedback from the lab will be incorporated into ongoing design refinement and verification planning, further advancing Vicarious Surgical's innovations in minimally invasive surgery.
Benzinga
5.0
01-05Benzinga
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
  • Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
  • Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
  • Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
  • Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
Businesswire
4.5
2025-12-29Businesswire
Vicarious Surgical Partners with Global Engineering Firm to Enhance Development Efficiency
  • Strategic Partnership Agreement: Vicarious Surgical has entered into a partnership with a global digital engineering firm to reduce operating costs and enhance development predictability and execution efficiency through a more effective mix of internal and external engineering resources.
  • Software Development Outsourcing: Under the agreement, the external partner will take on significant software development responsibilities for the Vicarious Surgical robotic system, including control systems and visualization components, which is expected to accelerate development speed and lower structural costs.
  • Operational Model Transformation: This collaboration allows internal teams to focus on core innovation and system integration, thereby improving the company's progress toward design freeze and clinical readiness while optimizing its cost structure.
  • Ongoing Transition Plan: The external engineering partner has begun onboarding through a structured transition plan that maintains continuity across all active workstreams, supporting the company's predictable progress toward key milestones.

Valuation Metrics

The current forward P/E ratio for Vicarious Surgical Inc (RBOT.N) is -0.52, compared to its 5-year average forward P/E of -5.83. For a more detailed relative valuation and DCF analysis to assess Vicarious Surgical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.83
Current PE
-0.52
Overvalued PE
2.55
Undervalued PE
-14.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.20
Current EV/EBITDA
-0.55
Overvalued EV/EBITDA
2.89
Undervalued EV/EBITDA
-9.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding RBOT

C
Comprehensive Financial Management LLC
Holding
RBOT
-13.80%
3M Return
A
Aspex Management (HK) Limited
Holding
RBOT
-17.52%
3M Return
K
Khosla Ventures, LLC
Holding
RBOT
-18.28%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Vicarious Surgical Inc (RBOT) stock price today?

The current price of RBOT is 0 USD — it has increased 0

What is Vicarious Surgical Inc (RBOT)'s business?

Vicarious Surgical Inc. is a robotics company, developing technology to improve surgical procedures. The Company is combining advanced miniaturized robotics, computer science, sensing and three-dimensional (3D) visualization to build a single-port surgical robot, called the Vicarious Surgical System, that helps surgeons to perform minimally invasive surgery. The Vicarious Surgical System is capable of incision sizes of approximately 1.8 centimeters. The Vicarious Surgical System consists of a camera and instrument arms, surgeon console and patient cart. The Vicarious Surgical System has a high-performance stereoscopic camera that, when combined with robotic motion, provides full 360-degree viewing capability and is being developed to continuously map the depth of the abdominal cavity. The Vicarious Surgical System surgeon console is designed to provide all the systems necessary for the surgeon in visualizing the surgical field and controlling all the motions of the robot.

What is the price predicton of RBOT Stock?

Wall Street analysts forecast RBOT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RBOT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Vicarious Surgical Inc (RBOT)'s revenue for the last quarter?

Vicarious Surgical Inc revenue for the last quarter amounts to -11.50M USD, decreased -35.21

What is Vicarious Surgical Inc (RBOT)'s earnings per share (EPS) for the last quarter?

Vicarious Surgical Inc. EPS for the last quarter amounts to -10581000.00 USD, decreased -16.61

How many employees does Vicarious Surgical Inc (RBOT). have?

Vicarious Surgical Inc (RBOT) has 123 emplpoyees as of April 01 2026.

What is Vicarious Surgical Inc (RBOT) market cap?

Today RBOT has the market capitalization of 40.98M USD.